JDOC vs. CNCR
Compare and contrast key facts about Jpmorgan Healthcare Leaders ETF (JDOC) and Loncar Cancer Immunotherapy ETF (CNCR).
JDOC and CNCR are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. JDOC is an actively managed fund by JPMorgan. It was launched on Nov 1, 2023. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015.
Performance
JDOC vs. CNCR - Performance Comparison
Loading graphics...
JDOC vs. CNCR - Yearly Performance Comparison
| 2026 (YTD) | |
|---|---|
JDOC Jpmorgan Healthcare Leaders ETF | -5.68% |
CNCR Loncar Cancer Immunotherapy ETF | 0.00% |
Returns By Period
JDOC
- 1D
- 2.32%
- 1M
- -6.11%
- YTD
- -3.96%
- 6M
- 6.94%
- 1Y
- 5.14%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CNCR
- 1D
- 0.00%
- 1M
- 0.00%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
JDOC vs. CNCR - Expense Ratio Comparison
JDOC has a 0.65% expense ratio, which is lower than CNCR's 0.79% expense ratio.
Return for Risk
JDOC vs. CNCR — Risk / Return Rank
JDOC
CNCR
JDOC vs. CNCR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Jpmorgan Healthcare Leaders ETF (JDOC) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| JDOC | CNCR | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.30 | — | — |
Sortino ratioReturn per unit of downside risk | 0.54 | — | — |
Omega ratioGain probability vs. loss probability | 1.07 | — | — |
Calmar ratioReturn relative to maximum drawdown | 0.54 | — | — |
Martin ratioReturn relative to average drawdown | 1.24 | — | — |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| JDOC | CNCR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.30 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.59 | — | — |
Dividends
JDOC vs. CNCR - Dividend Comparison
JDOC's dividend yield for the trailing twelve months is around 0.92%, while CNCR has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
JDOC Jpmorgan Healthcare Leaders ETF | 0.92% | 0.89% | 5.57% | 0.15% |
CNCR Loncar Cancer Immunotherapy ETF | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
JDOC vs. CNCR - Drawdown Comparison
The maximum JDOC drawdown since its inception was -20.87%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for JDOC and CNCR.
Loading graphics...
Drawdown Indicators
| JDOC | CNCR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -20.87% | 0.00% | -20.87% |
Max Drawdown (1Y)Largest decline over 1 year | -9.68% | — | — |
Current DrawdownCurrent decline from peak | -6.96% | 0.00% | -6.96% |
Average DrawdownAverage peak-to-trough decline | -7.01% | 0.00% | -7.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.61% | — | — |
Volatility
JDOC vs. CNCR - Volatility Comparison
Loading graphics...
Volatility by Period
| JDOC | CNCR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.67% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 10.15% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 17.04% | 0.00% | +17.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 14.33% | 0.00% | +14.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 14.33% | 0.00% | +14.33% |